Bristol Myers Squibb Partners with VantAI in $674M Deal to Develop Molecular Glue Therapies Using Generative AI

Feb 14, 2024 07:38 CST Updated 07:38

Proxima

AI Drug Discovery Company

Bristol-Myers Squibb

Biopharmaceutical and Nutritional Product R&D and Sales

▎WuXiEdited by Kant Content Team

Today, VantAI announced a strategic collaboration with Bristol-Myers Squibb to jointly discover new molecular glues targeting certain therapeutic targets.This collaboration leverages VantAI's geometric deep learning capabilities and Bristol-Myers Squibb's expertise in targeted protein degradation to discover and develop new small molecule therapies.

This collaboration will focus on leveraging VantAI's generative artificial intelligence platform to design molecular glues as small-molecule therapies. VantAI’s technology utilizes geometric deep learning to generate insights from millions of years of naturally occurring, evolving protein interfaces, allowing such interfaces to be mimicked during the design process.This "Protein Contact First (PCF)" approach simplifies the complex chemical design challenge of bringing proteins together in cells, yielding a more "glue-like" solution., and has optimized parameters, including efficacy, selectivity, and molecular size.

According to the agreement,VantAI is eligible to receive up to $674 million from Bristol-Myers Squibb in discovery, development, clinical, regulatory, and sales milestone payments., and can choose to further expand to other treatment programs.

The field of molecular glue has grown significantly in the past few years. Last year, Roche signed several related cooperation agreements, including a collaboration with Monte Rosa Therapeutics to target difficult-to-drug targets and through its...SubsidiaryGenentech's Molecular Glue Development Agreement with Orionis Biosciences. Additionally, MSD has also entered into a molecular glue development collaboration with Austrian biotech company Proxygen, which had previously collaborated with Boehringer Ingelheim and Merck KGaA.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi AppTec Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence. Retrieved February 13, 2024 from https://www.businesswire.com/news/home/20240213117969/en/VantAI-Enters-Collaboration-With-Bristol-Myers-Squibb-to-Accelerate-Molecular-Glue-Drug-Discovery-Through-Artificial-Intelligence

[2] BMS signs $674M biobucks pact with Roivant's VantAI for molecular glues. Retrieved February 13, 2024 from https://www.fiercebiotech.com/biotech/bms-and-roivants-vantai-go-after-molecular-glues-new-674m-deal

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.

Share，PointLike，In view，Focusing on Global Biomedical Health Innovation